 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...3456789101112131415 |
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment closed, Phase classification, Trial initiation date, Trial primary completion date: STREAM-2: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction (clinicaltrials.gov) - May 9, 2017
P4, N=600, Active, not recruiting, Sponsor: Katholieke Universiteit Leuven
Not yet recruiting --> Active, not recruiting | Phase classification: P2 --> P4 | Initiation date: Sep 2016 --> May 2017 | Trial primary completion date: Jun 2018 --> Jun 2020
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: THE NOR-TEST STUDY: Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke (clinicaltrials.gov) - Mar 28, 2017
P3, N=1050, Completed, Sponsor: Lars Thomassen
Not yet recruiting --> Active, not recruiting | Phase classification: P2 --> P4 | Initiation date: Sep 2016 --> May 2017 | Trial primary completion date: Jun 2018 --> Jun 2020 Recruiting --> Completed
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial primary completion date: TIAS: Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke (clinicaltrials.gov) - Oct 26, 2016
P2, N=20, Recruiting, Sponsor: University of Alberta
Recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial initiation date, Trial primary completion date, Head-to-Head: DIVA: Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion (clinicaltrials.gov) - Sep 23, 2016
P2, N=60, Not yet recruiting, Sponsor: University Hospital Center of Martinique
Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Apr 2015 --> Nov 2016 | Trial primary completion date: Dec 2015 --> Dec 2017
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: ATTEST2: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (clinicaltrials.gov) - Jun 27, 2016
P3, N=1870, Not yet recruiting, Sponsor: NHS Greater Glasgow and Clyde
- ||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2 trial: STREAM-2: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction (clinicaltrials.gov) - May 19, 2016
P2, N=600, Not yet recruiting, Sponsor: Katholieke Universiteit Leuven
- | Aggrastat (tirofiban) / Correvio, Medicure, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P4 trial: Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty (clinicaltrials.gov) - Oct 30, 2015
P4, N=1000, Recruiting, Sponsor: Xijing Hospital
- | Aggrastat (tirofiban) / Correvio, Medicure, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P4 trial: CocktailII: Cocktail Injection Improves Outcomes of FFR Guided PCI (clinicaltrials.gov) - Oct 30, 2015
P4, N=500, Recruiting, Sponsor: Xijing Hospital
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: THE NOR-TEST STUDY: Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke (clinicaltrials.gov) - Oct 28, 2015
P3, N=954, Recruiting, Sponsor: Lars Thomassen
Initiation date: Apr 2015 --> Nov 2016 | Trial primary completion date: Dec 2015 --> Dec 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial withdrawal: Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) (clinicaltrials.gov) - Sep 25, 2015
P2b, N=0, Withdrawn, Sponsor: Reza Behrouz, DO
Trial primary completion date: Jun 2016 --> Dec 2016 N=200 --> 0 | Not yet recruiting --> Withdrawn
- |||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment open: TEMPO-2: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (clinicaltrials.gov) - Jul 14, 2015
P3, N=1274, Recruiting, Sponsor: University of Calgary
N=200 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: EXTEND-IA TNK: Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (clinicaltrials.gov) - Apr 15, 2015
P2, N=64, Recruiting, Sponsor: Neuroscience Trials Australia
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P3 trial: TEMPO-2: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (clinicaltrials.gov) - Mar 25, 2015
P3, N=1274, Not yet recruiting, Sponsor: University of Calgary
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2 trial: EXTEND-IA TNK: Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (clinicaltrials.gov) - Mar 14, 2015
P2, N=64, Not yet recruiting, Sponsor: National Stroke Research Institute, Australia
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment change, Trial termination, Trial primary completion date: Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B) (clinicaltrials.gov) - Jan 20, 2015
P2b, N=112, Terminated, Sponsor: University of Virginia
Not yet recruiting --> Recruiting N=600 --> 112 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Mar 2009; Slow enrollment
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2 trial, Head-to-Head: DIVA: Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion (clinicaltrials.gov) - Jan 15, 2015
P2, N=60, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Fort-de-France
- || Fortelyzin (recombinant staphylokinase) / Supergene
New P3 trial: FORMAT-1: Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI (clinicaltrials.gov) - Nov 28, 2014
P3, N=392, Recruiting, Sponsor: Supergene, LLC
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion: TEMPO-1: TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion (clinicaltrials.gov) - Nov 24, 2014
P2, N=50, Completed, Sponsor: University of Calgary
N=600 --> 112 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Mar 2009; Slow enrollment Recruiting --> Completed
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Clinical: Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=987, Completed, Sponsor: Boehringer Ingelheim
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Clinical: Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=351, Completed, Sponsor: Boehringer Ingelheim
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Clinical: Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation (clinicaltrials.gov) - Jul 16, 2014
P=N/A, N=60, Completed, Sponsor: Boehringer Ingelheim
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P3 trial: ASSENT 3 Plus: A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting (clinicaltrials.gov) - Jul 8, 2014
P3, N=1606, Completed, Sponsor: Boehringer Ingelheim
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P3 trial: ASSENT 3: Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI) (clinicaltrials.gov) - Jul 8, 2014
P3, N=5989, Completed, Sponsor: Boehringer Ingelheim
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI) (clinicaltrials.gov) - Jul 8, 2014
P3, N=49, Completed, Sponsor: Boehringer Ingelheim
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2b trial: Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN) (clinicaltrials.gov) - Jul 2, 2014
P2b, N=200, Not yet recruiting, Sponsor: Reza Behrouz, DO
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2 trial: TIAS: Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke (clinicaltrials.gov) - Mar 31, 2014
P2, N=20, Recruiting, Sponsor: University of Alberta
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial withdrawal: Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study (clinicaltrials.gov) - Nov 3, 2013
P1, N=0, Withdrawn, Sponsor: Medical Center of Central Georgia
Recruiting --> Completed Recruiting --> Withdrawn
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment change: Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study (clinicaltrials.gov) - Nov 3, 2013
P1, N=0, Withdrawn, Sponsor: Medical Center of Central Georgia
Recruiting --> Withdrawn N=20 --> 0
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment change: A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI) (clinicaltrials.gov) - Oct 27, 2013
P4, N=1671, Terminated, Sponsor: Boehringer Ingelheim
N=20 --> 0 N=4000 --> 1671
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: THE NOR-TEST STUDY: Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke (clinicaltrials.gov) - Sep 23, 2013
P3, N=954, Recruiting, Sponsor: Lars Thomassen
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial termination: Clot Dissolving Treatment for Blood Clots in the Lungs (clinicaltrials.gov) - Aug 13, 2013
P3, N=87, Terminated, Sponsor: Jeffrey Kline
N=4000 --> 1671 Recruiting --> Terminated; PI changed institution and impossible to solve problem with contract's sites
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment change: Clot Dissolving Treatment for Blood Clots in the Lungs (clinicaltrials.gov) - Aug 13, 2013
P3, N=87, Terminated, Sponsor: Jeffrey Kline
Recruiting --> Terminated; PI changed institution and impossible to solve problem with contract's sites N=200 --> 87
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment closed: PEITHO Pulmonary Embolism Thrombolysis Study (clinicaltrials.gov) - Feb 5, 2013
P3, N=1005, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=200 --> 87 Recruiting --> Active, not recruiting
- ||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion: STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction (clinicaltrials.gov) - Oct 16, 2012
P3, N=1891, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST) (clinicaltrials.gov) - Aug 8, 2012
P2, N=104, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion: ICE T-TIMI 49: A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks (clinicaltrials.gov) - Aug 5, 2012
P2, N=40, Completed, Sponsor: C. Michael Gibson, MS, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2 trial: TEMPO-1: TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion (clinicaltrials.gov) - Jul 29, 2012
P2, N=50, Recruiting, Sponsor: University of Calgary
- || Clotinab (abciximab) / ISU Abxis, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P3 trial: INTRACORONARY ADMINISTRATION OF TENECTEPLASE VERSUS ABCIXIMAB AS ADJUNCTIVE TREATMENT DURING PRIMARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION OF ANTERIOR LOCATION ADMINISTRACION INTRACORONARIA DE TENECTEPLASA FRENTE A ABCIXIMAB COMO TRATAMIENTO ADJUNTO DURANTE ANGIOPLASTIA PRIMARIA EN INFARTO AGUDO DE MIOCARDIO DE LOCALIZACION ANTERIOR (EUDRACT) - Mar 27, 2012
P3, N=60, Ongoing, Sponsor: FRANCISCO JOSE MORALES PONCE
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2 trial: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST) (clinicaltrials.gov) - Nov 15, 2011
P2, N=104, Recruiting, Sponsor: NHS Greater Glasgow and Clyde